At present, the mainstream view is that the main mechanism of the Nrf2/HO-1 signaling pathway in the treatment of IBD involves controlling oxidative stress and reducing inflammatory damage [76,77], regulating intestinal microbiota to repair the intestinal mucosal barrier [78,79], and preventing the ferroptosis of intestinal epithelial cells [80,81]. The gene discussed is NFE2L2; the disease is inflammatory bowel disease.